Product Pathways - Apoptosis
SignalSilence® Bim siRNA I #6461
|6461S||300 µl (3 nmol)||---||In Stock||---|
|6461||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-), SignalSilence® Bim siRNA I (+) or SignalSilence® Bim siRNA II #6518 (+), using Bim (C34C5) Rabbit mAb and α-Tubulin (11H10) Rabbit mAb #2125. Bim (C34C5) rabbit mAb confirms silencing of Bim expression, while the α-tubulin (11H10) rabbit mAb is used to control for loading and specificity of Bim siRNA.
SignalSilence® Bim siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit Bim expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Directions For Use
CST recommends transfection with 100 nM Bim siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Bim/Bod is a pro-apoptotic protein belonging to the BH3-only group of Bcl-2 family members including Bad, Bid, Bik, Hrk, and Noxa that contain a BH3 domain but lack other conserved BH1 or BH2 domains (1,2). Bim induces apoptosis by binding to and antagonizing anti-apoptotic members of the Bcl-2 family. Interactions have been observed with Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bfl-1, and BHRF-1 (1,2). Bim functions in regulating apoptosis associated with thymocyte negative selection and following growth factor withdrawal, during which Bim expression is elevated (3-6). Three major isoforms of Bim are generated by alternative splicing: BimEL, BimL, and BimS (1). The shortest form, BimS, is the most cytotoxic and is generally only transiently expressed during apoptosis. The BimEL and BimL isoforms may be sequestered to the dynein motor complex through an interaction with the dynein light chain and released from this complex during apoptosis (7). Apoptotic activity of these longer isoforms may be regulated by phosphorylation (8,9). Environmental stress triggers Bim phosphorylation by JNK and results in its dissociation from the dynein complex and increased apoptotic activity.
Previous studies have shown that silencing of Bim using siRNA can reduce paclitaxel-induced apoptosis (8).
- O'Connor, L. et al. (1998) EMBO J 17, 384-95.
- Hsu, S.Y. et al. (1998) Mol Endocrinol 12, 1432-40.
- Bouillet, P. et al. (2002) Nature 415, 922-6.
- Whitfield, J. et al. (2001) Neuron 29, 629-43.
- Dijkers, P.F. et al. (2000) Curr Biol 10, 1201-4.
- Ley, R. et al. (2003) J Biol Chem 278, 18811-6.
- Puthalakath, H. et al. (1999) Mol Cell 3, 287-96.
- Lei, K. and Davis, R.J. (2003) Proc Natl Acad Sci U S A 100, 2432-7.
- Putcha, G.V. et al. (2003) Neuron 38, 899-914.
- Sunters, A. et al. (2003) J Biol Chem 278, 49795-805.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.